



LUND UNIVERSITY
Faculty of Medicine

LUP

Lund University Publications

Institutional Repository of Lund University

This is an author produced version of a paper published in Journal of molecular medicine-JMM. This paper has been peer-reviewed but does not include the final publisher proof-corrections or journal pagination.

Citation for the published paper:
Sonja Oehmcke, Heiko Herwald

"Contact system activation in severe infectious diseases."

Journal of molecular medicine-JMM 2010 88, 121 -
126

<http://dx.doi.org/10.1007/s00109-009-0564-y>

Access to the published version may require journal
subscription.

Published with permission from: Springer

Contact System Activation in Severe Infectious Diseases

Sonja Oehmcke[#] and Heiko Herwald

From the Department of Clinical Sciences, Division of Infection Medicine, Lund University, SE-22184 Lund, Sweden.

[#]To whom correspondence should be addressed: Department of Clinical Sciences, Division of Infection Medicine, BMC, B14, Lund University, Tornavägen 10, SE-221 84 Lund, Sweden, Phone +46-46-2228592, Fax +46-46-157756, e-mail sonja.oehmcke@med.lu.se

1 **Abstract**

2 Hemostasis is a sensitive and tightly regulated process, involving vascular
3 endothelium and blood cells as well as factors of the coagulation and fibrinolytic
4 cascades. In severe and invasive infectious diseases the equilibrium between the
5 procoagulant and anticoagulant status of the host may change dramatically and can
6 induce life-threatening complications. A growing body of evidence suggests that the
7 contact system, also known as the intrinsic pathway of coagulation or kallikrein/kinin
8 system, participate in these processes. Contact activation leads to the release of the
9 highly potent proinflammatory peptide bradykinin and initiates the intrinsic pathway of
10 coagulation. Several studies have shown a systemic activation of the contact system
11 in animal models of severe bacterial infections and similar findings were also
12 reported when monitoring patients suffering from sepsis, severe sepsis, or septic
13 shock. Complications resulting from a systemic activation of the contact system are
14 pathologically high levels of bradykinin, consumption of contact factors, and a
15 subsequent induction of inflammatory reactions. These conditions may contribute to
16 serious complications such as hypotension and vascular leakage. Here we
17 summarize the state of the art in this field of research with a focus on the contact
18 system and we also discuss a potential role for the contact system as a target for the
19 development of novel antimicrobial strategies.

20

21

1 **Introduction**

2 Sepsis, severe sepsis, and septic shock are complications derived from bacterial
3 infections that are the second leading cause of death among patients in non-coronary
4 intensive care units and the 10th leading cause of death in the United States [1].
5 Despite treatment with antibiotics and an improved intensive care system, the
6 incidence of sepsis and the number of sepsis-related deaths are increasing and they
7 are associated with mortality rates between 30 and 70% [2]. The molecular
8 mechanisms behind the pathogenesis of these life-threatening conditions are still not
9 fully understood. A growing body of evidence, however, suggests that the interaction
10 between bacterial pathogens and the host defense machinery results in an
11 uncontrolled and overwhelming inflammatory response. This includes a systemic
12 activation of proteolytic host cascades such as the complement and coagulation
13 cascades as well as the contact system, also known as the kallikrein/kinin system or
14 intrinsic pathway of coagulation [3].

15
16 **The contact system**

17 Once activated the contact system is involved in the regulation of hemostatic and
18 inflammatory processes [4, 5]. The system contains 4 components: three serine
19 proteinases: factor XI (FXI), factor XII (FXII), plasma kallikrein, and the non-
20 enzymatic co-factor, high molecular weight kininogen (HK), respectively. The latter
21 protein consists of six domains, of which domain 1 – 3 are cystatin-like. The
22 bradykinin sequence is found in domain 4, and domain 5 carries a zinc-binding site
23 and a binding site for negatively charged surfaces [4-7]. As early as 1995 it was
24 shown that HKH20, a peptide derived from HK domain 5 (amino acids 479 to 498),
25 spanning the binding site for negatively charges surfaces, is able to interact with M
26 protein, an important streptococcal virulence factor [6]. Thereafter, it was also
27 reported that HKH20 mimics the HK binding site to many eukaryotic cell types [8-10],
28 binds to lipopolysaccharide [11], and has antimicrobial activity [12]. In addition
29 another HK-derived peptide (amino acids 420 to 513) covering the HKH20 sequence
30 was found to down-regulate endothelial cell proliferation and migration and inhibit
31 angiogenesis [13]. Finally, domain 6 mediates the binding to plasma kallikrein and
32 FXI [14].

33 The four contact factors normally circulate in the bloodstream or are bound to the
34 surface of different cell types, including endothelial cells, platelets and
35 polymorphonuclear neutrophils (PMNs). Negatively charged surfaces such as kaolin
36 and dextran-sulfate as well as nucleotides (DNA and RNA) have been reported to
37 assemble and activate the contact system [10, 15-17]. While the molecular

1 mechanisms leading to a contact activation on kaolin and dextran-sulfate are more or
2 less understood, there are controversial reports addressing the mode of activation on
3 cellular surfaces. Therefore, the latter will not be discussed in this article. FXII bound
4 to kaolin is converted into an active proteinase (FXIIa) by autoactivation. This is
5 followed by a FXIIa-mediated activation of plasma kallikrein, a process referred to as
6 limited proteolysis. Plasma kallikrein in turn is able to increase of the activity of FXIIa,
7 which then enables FXIIa to activate FXI and subsequently the intrinsic pathway of
8 coagulation (Fig.1) eventually leading to the formation of a fibrin network.

9 Inflammatory reactions are evoked by the processing of HK via plasma kallikrein,
10 resulting in the release of bradykinin (BK) from its precursor. BK is a potent
11 multifunctional pro-inflammatory peptide consisting of nine amino acids. Many effects
12 of BK are induced by its ability to trigger the induction of second-generation
13 mediators such as nitric oxide, prostaglandins and leukotrienes. In addition BK is
14 involved in many other processes such as the regulation of blood pressure, induction
15 of fever, increase of vascular permeability and capillary leakage, edema formation,
16 and hypotension [4, 5]. Notably, the half-life of BK in the circulation is extremely short
17 (< 10 seconds) and thus, increased levels of BK in patients with various underlying
18 diseases are difficult to monitor. There are, however, two conditions that are
19 associated with high levels of BK namely hereditary angioedema (caused by a
20 deficiency of C1-inhibitor, an inhibitor of the contact and the complement system) and
21 severe infectious diseases (for reviews see [18, 19]).

23 **Sepsis and Coagulation**

24 Sepsis is defined as a systemic inflammatory response syndrome (SIRS) with an
25 underlying infection. Complications from these life-threatening conditions are often
26 expanded when the initial appropriate host response to the invading pathogen is
27 amplified and becomes deleterious. Clinical symptoms of the onset are frequently
28 conflictive (fever or hypothermia, tachycardia, leukocytosis or leucopenia), and if
29 untreated, patients may develop respiratory or renal failure, coagulopathy and non-
30 responsive hypotension. The immunological reactions under these conditions are
31 complex and can alter over time. The early proinflammatory response is
32 characterized by an overwhelming stimulus and triggers PMNs and macrophages to
33 an excessive production of cytokines, chemokines, and other proinflammatory
34 mediators. Other complications, such as secondary ischemia (shock) and hypoxia
35 (lung injury) can also amplify the proinflammatory response [20]. This boost of
36 inflammatory reactions may lead to a shift from a normally beneficial inflammatory
37 response to hyper-inflammatory and counterproductive reactions, which eventually

1 cause more damage than the host can tolerate. It is now believed that the initial
2 hyper-inflammatory phase accounts for some early deaths, although most patients
3 die at later stages due to their prolonged immunosuppressive state [21].

4 Studies of host-parasite interactions taking place in the circulation have significantly
5 contributed to our understanding of the molecular mechanisms that lead to the
6 induction of systemic inflammatory reaction. Host effectors systems that are of
7 interest here are the contact-, complement-, fibrinolytic-, and coagulation systems.
8 The latter is activated by the induction of tissue factor (TF) expression on
9 mononuclear and endothelial cells, which is often triggered by bacteria or bacterial
10 products [22]. An up-regulation of TF on the surface of these cells can lead to a
11 systemic activation of the coagulation system that may progress to additional
12 complications such as disseminated intravascular coagulation (DIC). DIC is
13 characterized by the formation of microthrombi in microvasculature [23]. At the initial
14 stage clot formation occurs intra - and extravascularly due to thrombin activation
15 (hypercoagulopathy) and is followed by a consumption of coagulation factors
16 combined with a platelet dysfunction (hypocoagulability). This chain of events leaves
17 the patients in a paradoxical situation, where microvascular thrombus formation
18 causes a perturbation in the microcirculation, leading to multiple organ failure,
19 complicated by impairment of fibrinolysis. On the other hand patients experience a
20 high risk for severe bleeding due to depletion of coagulation factors and platelets
21 [24].

23 **Contact activation in severe infectious diseases**

24 With regard to the role of the contact system in severe infectious diseases it should
25 be noted that it was already in 1970 reported that patients with hypotensive sepsis
26 have significantly lower levels of contact factors in their blood than patients with
27 sepsis alone [25]. Since then, several studies have been published showing that
28 systemic contact activation has been found in patients with severe sepsis, septic
29 shock and sepsis combined with SIRS and that this is often combined with a massive
30 release of BK and a consumption of contact factors [26-28]. Notably, low levels of
31 plasma kallikrein, FXII and HK during sepsis correlate with a fatal outcome of the
32 disease [26, 29].

33 Until recently it was generally accepted that the contact system plays a secondary
34 role in hemostasis, since patients with deficiencies in FXII, plasma kallikrein, or HK
35 do not suffer from bleeding disorders. This point of view changed when the first data
36 on FXI and FXII deficient mice were published and it was found that contact
37 activation contributes to pathological thrombus formation in response to vessel injury

1 [30, 31]. Whether the contact system contributes to pathologic coagulation disorders
2 in severe infectious diseases is controversial and discussed. For instance, Pixley and
3 colleagues reported that contact activation occurs in patients with DIC [32].
4 Pronounced activation of the system was also seen in children with meningococcal
5 septic shock [33, 34] and in patients with streptococcal toxic shock syndrome (STSS)
6 [35]. On the other hand it has been found that patients with STSS but without a
7 bleeding tendency, had a prolonged aPTT [35], implying that contact activation has
8 occurred. The latter findings are in line with an experimental baboon model of lethal
9 *E. coli* bacteremia, showing that systemic contact activation is not combined with
10 DIC, but with fatal hypotension, probably caused by the release of BK [36, 37]. It is
11 noteworthy to mention that animals experienced an initial hypotension that was
12 reversed, when treated with a human antibody against FXII and extended the life of
13 the baboons [36]. However, more studies are required to unravel the role of the
14 contact system in the induction of coagulation disorders in severe infectious
15 diseases.

16

17 **Contact activation and inflammation**

18 The release of BK from HK is responsible for evoking inflammatory reactions [38].
19 There are two types of kinin receptors in humans, termed B1 and B2 receptors. Mice
20 lacking both receptors have normal blood pressure and cardiac morphology and they
21 are unable to respond to stimulation with kinins [39]. Importantly, lipopolysaccharide
22 (LPS) challenge in B1B2^{-/-} mice does not affect the blood pressure in these animals,
23 while blood pressure was markedly decreased in wild-type animals [39]. Other
24 studies have shown a protective effect of kinin antagonists in a lethal LPS model in
25 rats [40]. With regards to the molecular mechanisms leading to the induction of these
26 inflammatory reactions, Fischer *et al.* conducted experiments showing that BK-
27 induced vasoconstriction in a rat LPS model can be prevented by the application of
28 cyclooxygenase inhibitors and is dependent on the inducible nitric oxide synthase
29 [41, 42]. These findings imply that the induction of second-generation mediators by
30 kinins significantly contribute to the inflammatory reactions seen in the LPS
31 challenged animals. Interestingly, many bacterial proteinases have evolved
32 mechanisms to trigger the release of BK from HK, either by cleaving HK directly or by
33 activating PK. One of the first reports was already published in 1984 by Matsumoto
34 and colleagues who described a metallo protease from *Serratia marcescens* with
35 plasma kallikrein-like properties [43]. Since then, bacterial proteinases from many
36 other bacterial species have been described to activate the contact system in one
37 way or another (for a review see [44]). It has been suggested that the vascular

1 permeability induced by the released kinins promotes an influx of plasma into the site
2 of infection that serves as nutrients and facilitates spreading of the microorganisms
3 within the infected host [44].
4

5 **Contact activation caused by microorganisms**

6 As early as 1983 it was shown by Kalter *et al.* that LPS of Gram-negative bacteria as
7 well as peptidoglycan and teichoic acid of Gram-positive bacteria have the ability to
8 induce activation of the contact system [45]. While the LPS binding-site in HK was
9 recently resolved [46], no information on the interaction sites between peptidoglycans
10 and teichoic acid with contact factors has been published to date. Subsequent
11 studies have shown that bacterial surface proteins, such as M protein of
12 *Streptococcus pyogenes* or thin aggregative fimbriae expressed by *Escherichia coli*
13 and *Salmonella*, are able to bind and assemble contact factors on their surfaces and
14 trigger the activation of the system [6, 47]. An activation of the contact system by
15 *Staphylococcus aureus* and *Rickettsia rickettsii* has also been described [7, 48]
16 although the bacterial proteins that promote the binding to the contact factors have
17 not yet been identified. In addition, and as mentioned above, many bacterial
18 proteinases have been described to cleave HK and release BK, and recently it has
19 been reported that fungal pathogens also (*Candida* species) interact with factors of
20 the contact system [49].
21

22 **Contact System Inhibition – a potential therapeutic intervention?**

23 One can wonder whether the contact system is an interesting target for drug
24 development, as it also has protective effects. For instance, it plays an important role
25 in innate immunity via the generation of HK-derived antibacterial peptides and kinin
26 induced recruitment of neutrophils [50-52]. However, these responses take place at
27 an early stage and are most likely restricted to the site of infection, while under
28 systemic conditions a massive activation of the contact system may lead to the
29 release of pathologic levels of kinins and a consumption of contact factors (for a
30 review see [26]). Notably, low levels of some contact factors are an indication of an
31 unfavorable outcome of the disease [26]. The prevention of a systemic activation
32 could therefore benefit seriously ill patients.

33 Kinins are potent inflammatory mediators, causing symptoms such as increased
34 vascular permeability, vascular leakage, hypotension and edema formation, which
35 are a hallmark of severe infectious diseases. Kinin receptors are therefore attractive
36 targets for drug development. Two receptors (B1R and B2R) have been described in
37 humans, of which both have completely different pharmacologic profiles (for a review

1 see [53]). B2R is constitutively expressed by most cell types and rapidly internalized
2 upon BK binding [53], while B1R is generally expressed at a low level in normal
3 tissue, but up-regulated upon stimulation with proinflammatory agents such as LPS
4 or endotoxins from *S. aureus* and *S. pyogenes* [54-56]. A number of kinin receptor
5 antagonists have been developed and successfully used in animal models [57].
6 However, so far only a B2R antagonist (Deltibant) has been used in clinical trials for
7 sepsis [58]. The drug was used in patients with SIRS and presumed sepsis in a
8 randomized, double-blind, placebo-controlled trial. Deltibant observed no significant
9 effect on risk-adjusted 28-day survival, but posthoc analysis of risk-adjusted 7-day
10 survival showed a non-significant trend toward improvement. Furthermore, the 28-
11 day risk-adjusted survival in the prospectively defined subset of patients with Gram-
12 negative infections showed a statistically significant improvement [58]. Considering
13 the important role of the B1R in infectious diseases [59], theoretically, a combination
14 of B1R and B2R antagonists could be an interesting alternative approach for a
15 clinical trial.

16 C1 inhibitor is a member of the family of serine proteinase inhibitors and a major
17 regulator of the complement and contact systems. It has been reported that levels of
18 proteolytically inactivated C1 inhibitor are increased in septic patients [60]. Notably,
19 treatment with C1 inhibitor during sepsis attenuated contact activation and had a
20 beneficial effect on hypotension and renal dysfunction [61-63]. The results from
21 clinical studies, therefore, indicate that therapeutic administration of C1 inhibitor may
22 be safe, even though major bleedings have been observed in patients as compared
23 to the control groups [62]. It should be noted that C1 inhibitor inhibits serine
24 proteases irreversibly and may also block other proteases from the coagulation
25 cascade, if applied in therapeutic doses.

26 A completely different mode of contact system inhibition was recently reported in a
27 mouse model of invasive streptococcal infections. In this study a synthetic peptide
28 derived from domain 5 of HK, resembling the binding site to eukaryotic and bacterial
29 surfaces (see above), was shown to prevent activation of the contact system on
30 these surfaces [64]. Treatment with the peptide protected mice with invasive
31 *Streptococcus pyogenes* infection from lung damage and, in combination with
32 clindamycin, the peptide also significantly improved the overall survival. However, the
33 peptide has not been used in clinical trials yet.

34

35 **Concluding remarks**

36 Therapies in sepsis, severe sepsis, and septic shock, which are entirely based on
37 antibiotics, are combined with a high risk to fail, and thus, there is an urgent need for

1 novel antimicrobial strategies. Concepts focusing on the prevention of patho-
2 physiological mechanisms in severe infectious diseases, such as the systemic
3 activation of important host effector systems, are therefore promising and may have
4 a considerable impact. For instance, treatment with activated protein C (APC) has
5 been found to reduce the mortality in severe sepsis patients [65]. However, APC
6 administration is combined with severe side effects (bleeding) and, thus, its
7 application is restricted to patients at high risk of death.

8 Patients with deficiencies in FXII, plasma kallikrein, or HK do not experience severe
9 bleeding disorders. The inhibition of the contact system at the initial stage of an
10 infection is therefore an interesting therapeutic approach to prevent hyper-
11 inflammatory reactions. This concept is in line with findings that the treatment of
12 sepsis patients with C1 inhibitor results in a beneficial clinical outcome. However, the
13 study also showed that patients still suffer from severe bleedings, probably because
14 C1 inhibitor also targets other coagulation factors apart from plasma kallikrein. It is
15 therefore tempting to speculate that more specific contact inhibitors with a safer
16 pharmacologic profile are promising candidates for the development of novel
17 antimicrobial therapies.

18

1 **Acknowledgements**

2 This work was supported in part by the foundations of Alfred Österlund, Crafoord,
3 Greta and Johan Kock, the Blood and Defence Network and the Vascular Wall
4 Programme at Lund University, the Medical Faculty, Lund University, the Swedish
5 Research Council, and Hansa Medical. Hansa Medical, that in part funded this study
6 has filed patent applications on HKH20. SO and HH are listed as inventors and the
7 applications are pending.

8

9

10 **Keywords**

11 Sepsis, coagulation, contact system, *Streptococcus pyogenes*

12

1 References

2

3 1. Martin GS, Mannino DM, Eaton S, Moss M (2003) The epidemiology of
4 sepsis in the United States from 1979 through 2000. *N Engl J Med* 348: 1546-1554

5 2. Riedemann NC, Guo RF, Ward PA (2003) Novel strategies for the treatment
6 of sepsis. *Nat Med* 9: 517-524. DOI 10.1038/nm0503-517
7 nm0503-517 [pii]

8 3. Pixley RA, Zellis S, Bankes P, DeLa Cadena RA, Page JD, Scott CF,
9 Kappelmayer J, Wyshock EG, Kelly JJ, Colman RW (1995) Prognostic value of
10 assessing contact system activation and factor V in systemic inflammatory response
11 syndrome. *Crit Care Med* 23: 41-51

12 4. Hasan AA, Cines DB, Herwald H, Schmaier AH, Müller-Esterl W (1995)
13 Mapping the cell binding site on high molecular weight kininogen domain 5. *J*
14 *BiolChem* 270: 19256-19261

15 5. Herwald H, Mörgelin M, Svensson HG, Sjöbring U (2001) Zinc-dependent
16 conformational changes in domain D5 of high molecular mass kininogen modulate
17 contact activation. *Eur J Biochem* 268: 396-404

18 6. Ben Nasr AB, Herwald H, Müller-Esterl W, Björck L (1995) Human
19 kininogens interact with M protein, a bacterial surface protein and virulence
20 determinant. *Biochem J* 305: 173-180

21 7. Mattsson E, Herwald H, Cramer H, Persson K, Sjöbring U, Björck L (2001)
22 *Staphylococcus aureus* induces release of bradykinin in human plasma. *Infect Immun*
23 69: 3877-3882

24 8. Herwald H, Dedio J, Kellner R, Loos M, Müller-Esterl W (1996) Isolation and
25 characterization of the kininogen-binding protein p33 from endothelial cells. Identity
26 with the gC1q receptor. *J Biol Chem* 271: 13040-13047

27 9. Mahdi F, Shariat-Madar Z, Kuo A, Carinato M, Cines DB, Schmaier AH
28 (2004) Mapping the interaction between high molecular mass kininogen and the
29 urokinase plasminogen activator receptor. *J Biol Chem* 279: 16621-16628. DOI
30 10.1074/jbc.M313850200
31 M313850200 [pii]

32 10. Nakazawa Y, Joseph K, Kaplan AP (2002) Inhibition of contact activation by
33 a kininogen peptide (HKH20) derived from domain 5. *International*
34 *immunopharmacology* 2: 1875-1885. DOI S1567-5769(02)00182-0 [pii]

35 11. Perkins R, Ngo MD, Mahdi F, Shariat-Madar Z (2008) Identification of
36 lipopolysaccharide binding site on high molecular weight kininogen. *Biochem*
37 *Biophys Res Commun* 366: 938-943. DOI S0006-291X(07)02654-X [pii]
38 [10.1016/j.bbrc.2007.12.042](https://doi.org/10.1016/j.bbrc.2007.12.042)

39 12. Nordahl EA, Rydengård V, Mörgelin M, Schmidtchen A (2005) Domain 5 of
40 high molecular weight kininogen is antibacterial. *J Biol Chem* 280: 34832-34839

41 13. Colman RW, Jameson BA, Lin Y, Johnson D, Mousa SA (2000) Domain 5 of
42 high molecular weight kininogen (kininostatin) down-regulates endothelial cell
43 proliferation and migration and inhibits angiogenesis. *Blood* 95: 543-550

44 14. Colman RW, Schmaier AH (1997) Contact system: a vascular biology
45 modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory
46 attributes. *Blood* 90: 3819-3843


47 15. Kunapuli SP, DeLa Cadena RA, Colman RW (1993) Deletion mutagenesis of
48 high molecular weight kininogen light chain. Identification of two anionic surface
49 binding subdomains. *J Biol Chem* 268: 2486-2492

- 1 16. Kannemeier C, Shibamiya A, Nakazawa F, Trusheim H, Ruppert C, Markart
2 P, Song Y, Tzima E, Kennerknecht E, Niepmann M, von Bruehl ML, Sedding D,
3 Massberg S, Günther A, Engelmann B, Preissner KT (2007) Extracellular RNA
4 constitutes a natural procoagulant cofactor in blood coagulation. *Proceedings of the*
5 *National Academy of Sciences of the United States of America* 104: 6388-6393. DOI
6 0608647104 [pii]
7 10.1073/pnas.0608647104
- 8 17. Oehmcke S, Mörgelin M, Herwald H (2009) Activation of the human contact
9 system on neutrophil extracellular traps. *J Innate Immun* 1: 225-231
- 10 18. Davis AE, 3rd (2008) Hereditary angioedema: a current state-of-the-art
11 review, III: mechanisms of hereditary angioedema. *Ann Allergy Asthma Immunol*
12 100: S7-12
- 13 19. Frick IM, Björck L, Herwald H (2007) The dual role of the contact system in
14 bacterial infectious disease. *Thromb Haemost* 98: 497-502
- 15 20. Russell JA (2006) Management of sepsis. *N Engl J Med* 355: 1699-1713
- 16 21. Rittirsch D, Flierl MA, Ward PA (2008) Harmful molecular mechanisms in
17 sepsis. *Nat Rev Immunol* 8: 776-787. DOI nri2402 [pii]
18 10.1038/nri2402
- 19 22. Fourier F, Jourdain M, Tournois A, Caron C, Goudemand J, Chopin C (1995)
20 Coagulation inhibitor substitution during sepsis. *Intensive Care Med* 21 Suppl 2:
21 S264-268
- 22 23. Risberg B, Andreasson S, Eriksson E (1991) Disseminated intravascular
23 coagulation. *Acta Anaesthesiol Scand Suppl* 95: 60-71
- 24 24. Levi M, Ten Cate H (1999) Disseminated intravascular coagulation. *N Engl J*
25 *Med* 341: 586-592
- 26 25. Mason JW, Kleeberg U, Dolan P, Colman RW (1970) Plasma kallikrein and
27 Hageman factor in Gram-negative bacteremia. *Ann Intern Med* 73: 545-551
- 28 26. Pixley RA, Colman RW (1997) The kallikrein-kinin system in sepsis
29 syndrome. *Handbook of Immunopharmacology - The Kinin System* Farmer SG, ed
30 New York: Academic Press: 173-186
- 31 27. Saugstad OD, Buo L, Johansen HT, Roise O, Aasen AO (1992) Activation of
32 the plasma kallikrein-kinin system in respiratory distress syndrome. *Pediatr Res* 32:
33 431-435
- 34 28. Mattsson E, Herwald H, Cramer H, Persson K, Sjöbring U, Björck L (2001)
35 *Staphylococcus aureus* induces release of bradykinin in human plasma. *Infect Immun*
36 69: 3877-3882. DOI 10.1128/IAI.69.6.3877-3882.2001
- 37 29. Aasen AO, Smith-Erichsen N, Amundsen E (1983) Plasma kallikrein-kinin
38 system in septicemia. *Arch Surg* 118: 343-346
- 39 30. Renne T, Pozgajova M, Gruner S, Schuh K, Pauer HU, Burfeind P, Gailani D,
40 Nieswandt B (2005) Defective thrombus formation in mice lacking coagulation factor
41 XII. *J Exp Med* 202: 271-281. DOI jem.20050664 [pii]
42 10.1084/jem.20050664
- 43 31. Gailani D, Renne T (2007) Intrinsic pathway of coagulation and arterial
44 thrombosis. *Arterioscler Thromb Vasc Biol* 27: 2507-2513. DOI
45 ATVBAHA.107.155952 [pii]
46 10.1161/ATVBAHA.107.155952
- 47 32. Kaufman N, Page JD, Pixley RA, Schein R, Schmaier AH, Colman RW
48 (1991) Alpha 2-macroglobulin-kallikrein complexes detect contact system activation
49 in hereditary angioedema and human sepsis. *Blood* 77: 2660-2667

- 1 33. van Deuren M, Brandtzaeg P, van der Meer JW (2000) Update on
2 meningococcal disease with emphasis on pathogenesis and clinical management. Clin
3 Microbiol Rev 13: 144-166
- 4 34. Wuillemin WA, Fijnvandraat K, Derkx BH, Peters M, Vreede W, ten Cate H,
5 Hack CE (1995) Activation of the intrinsic pathway of coagulation in children with
6 meningococcal septic shock. Thromb Haemost 74: 1436-1441
- 7 35. Sriskandan S, Cohen J (2000) Kallikrein-kinin system activation in
8 streptococcal toxic shock syndrome. Clin Infect Dis 30: 961-962
- 9 36. Pixley RA, De La Cadena R, Page JD, Kaufman N, Wyshock EG, Chang A,
10 Taylor FBJ, Colman RW (1993) The contact system contributes to hypotension but
11 not disseminated intravascular coagulation in lethal bacteremia. In vivo use of a
12 monoclonal anti-factor XII antibody to block contact activation in baboons. J Clin
13 Invest 91: 61-68
- 14 37. Pixley RA, DeLa Cadena RA, Page JD, Kaufman N, Wyshock EG, Colman
15 RW, Chang A, Taylor FB, Jr. (1992) Activation of the contact system in lethal
16 hypotensive bacteremia in a baboon model. Am J Pathol 140: 897-906
- 17 38. Campbell DJ (2001) The kallikrein-kinin system in humans. Clin Exp
18 Pharmacol Physiol 28: 1060-1065
- 19 39. Cayla C, Todiras M, Iliescu R, Saul VV, Gross V, Pilz B, Chai G, Merino VF,
20 Pesquero JB, Baltatu OC, Bader M (2007) Mice deficient for both kinin receptors are
21 normotensive and protected from endotoxin-induced hypotension. FASEB J 21: 1689-
22 1698. DOI fj.06-7175com [pii]
23 10.1096/fj.06-7175com
- 24 40. Morinelli TA, Webb JG, Jaffa AA, Privitera PJ, Margolius HS (2001) A
25 metabolic fragment of bradykinin, Arg-Pro-Pro-Gly-Phe, protects against the
26 deleterious effects of lipopolysaccharide in rats. J Pharmacol Exp Ther 296: 71-76
- 27 41. Fischer LG, Hollmann MW, Horstman DJ, Rich GF (2000) Cyclooxygenase
28 inhibitors attenuate bradykinin-induced vasoconstriction in septic isolated rat lungs.
29 Anesth Analg 90: 625-631
- 30 42. Fischer LG, Hilpert JH, Freise H, Wendholt D, Van Aken H, Sielenkamper
31 AW (2004) Bradykinin-induced pulmonary vasoconstriction is time and inducible
32 nitric oxide synthase dependent in a peritonitis sepsis model. Anesth Analg 99: 864-
33 871. DOI 10.1213/01.ANE.0000133000.65613.F5
34 99/3/864 [pii]
- 35 43. Matsumoto K, Yamamoto T, Kamata R, Maeda H (1984) Pathogenesis of
36 serratal infection: activation of the Hageman factor-prekallikrein cascade by serratal
37 protease. J Biochem 96: 739-749
- 38 44. Potempa J, Pike RN (2009) Corruption of Innate Immunity by Bacterial
39 Proteases. J Innate Immun 1: 70-87
- 40 45. Kalter ES, van Dijk WC, Timmerman A, Verhoef J, Bouma BN (1983)
41 Activation of purified human plasma prekallikrein triggered by cell wall fractions of
42 *Escherichia coli* and *Staphylococcus aureus*. J Infect Dis 148: 682-691
- 43 46. Perkins R, Ngo MD, Mahdi F, Shariat-Madar Z (2008) Identification of
44 lipopolysaccharide binding site on high molecular weight kininogen. Biochem
45 Biophys Res Commun 366: 938-943. DOI S0006-291X(07)02654-X [pii]
46 10.1016/j.bbrc.2007.12.042
- 47 47. Herwald H, Mörgelin M, Olsén A, Rhen M, Dahlbäck B, Müller-Esterl W,
48 Björck L (1998) Activation of the contact-phase system on bacterial surfaces--a clue
49 to serious complications in infectious diseases. Nat Med 4: 298-302

- 1 48. Yamada T, Harber P, Pettit GW, Wing DA, Oster CN (1978) Activation of the
2 kallikrein-kinin system in Rocky Mountain spotted fever. *Ann Intern Med* 88: 764-
3 768
- 4 49. Rapala-Kozik M, Karkowska J, Jacher A, Golda A, Barbasz A, Guevara-Lora
5 I, Kozik A (2008) Kininogen adsorption to the cell surface of *Candida* spp.
6 *International immunopharmacology* 8: 237-241
- 7 50. Andersson Nordahl E, Rydengård V, Mörgelin M, Schmidtchen A (2005)
8 Domain 5 of high molecular weight kininogen is antibacterial. *J Biol Chem* in press
- 9 51. Araujo RC, Kettritz R, Fichtner I, Paiva AC, Pesquero JB, Bader M (2001)
10 Altered neutrophil homeostasis in kinin B1 receptor-deficient mice. *Biol Chem* 382:
11 91-95. DOI 10.1515/BC.2001.014
- 12 52. Frick IM, Akesson P, Herwald H, Mörgelin M, Malmsten M, Nagler DK,
13 Björck L (2006) The contact system-a novel branch of innate immunity generating
14 antibacterial peptides. *EMBO J* 25: 5569-5578
- 15 53. Leeb-Lundberg LM, Marceau F, Müller-Esterl W, Pettibone DJ, Zuraw BL
16 (2005) International union of pharmacology. XLV. Classification of the kinin receptor
17 family: from molecular mechanisms to pathophysiological consequences. *Pharmacol*
18 *Rev* 57: 27-77. DOI 57/1/27 [pii]
19 10.1124/pr.57.1.2
- 20 54. Schremmer-Danninger E, Offner A, Siebeck M, Roscher AA (1998) B1
21 bradykinin receptors and carboxypeptidase M are both upregulated in the aorta of pigs
22 after LPS infusion. *Biochemical and biophysical research communications* 243: 246-
23 252. DOI S0006-291X(97)97999-7 [pii]
24 10.1006/bbrc.1997.7999
- 25 55. Bengtson SH, Phagoo SB, Norrby-Teglund A, Pählman L, Mörgelin M,
26 Zuraw BL, Leeb-Lundberg LMF, Herwald H (2006) Kinin receptor expression during
27 *Staphylococcus aureus* infection. *Blood* 108: 2055-2063
- 28 56. Bengtson SH, Sandén C, Mörgelin M, Marx PF, Leeb-Lundberg FLM,
29 Meijers JCM, Herwald H (2009) Activation of TAFI on the surface of *Streptococcus*
30 *pyogenes* evokes inflammatory reactions by modulating the kallikrein/kinin system. *J*
31 *Innate Immun* 1: 18-28
- 32 57. Marceau F, Regoli D (2004) Bradykinin receptor ligands: therapeutic
33 perspectives. *Nat Rev Drug Discov* 3: 845-852
- 34 58. Fein AM, Bernard GR, Criner GJ, Fletcher EC, Good JT, Jr., Knaus WA,
35 Levy H, Matuschak GM, Shanies HM, Taylor RW, Rodell TC (1997) Treatment of
36 severe systemic inflammatory response syndrome and sepsis with a novel bradykinin
37 antagonist, deltibant (CP-0127). Results of a randomized, double-blind, placebo-
38 controlled trial. CP-0127 SIRS and Sepsis Study Group. *Jama* 277: 482-487
- 39 59. Merino VF, Todiras M, Campos LA, Saul V, Popova E, Baltatu OC, Pesquero
40 JB, Bader M (2008) Increased susceptibility to endotoxic shock in transgenic rats with
41 endothelial overexpression of kinin B(1) receptors. *J Mol Med* 86: 791-798. DOI
42 10.1007/s00109-008-0345-z
- 43 60. Nuijens JH, Eerenberg-Belmer AJ, Huijbregts CC, Schreuder WO, Felt-
44 Bersma RJ, Abbink JJ, Thijs LG, Hack CE (1989) Proteolytic inactivation of plasma
45 C1- inhibitor in sepsis. *The Journal of clinical investigation* 84: 443-450
- 46 61. Caliezi C, Wuillemin WA, Zeerleder S, Redondo M, Eisele B, Hack CE
47 (2000) C1-Esterase Inhibitor: An Anti-Inflammatory Agent and Its Potential Use in
48 the Treatment of Diseases Other Than Hereditary Angioedema. *Pharmacol Rev* 52:
49 91-112

- 1 62. Caliezi C, Zeerleder S, Redondo M, Regli B, Rothen HU, Zurcher-Zenklusen
2 R, Rieben R, Devay J, Hack CE, Lammler B, Wuillemin WA (2002) C1-inhibitor in
3 patients with severe sepsis and septic shock: beneficial effect on renal dysfunction.
4 *Critical care medicine* 30: 1722-1728
- 5 63. Hack CE, Ogilvie AC, Eisele B, Eerenberg AJ, Wagstaff J, Thijs LG (1993)
6 C1-inhibitor substitution therapy in septic shock and in the vascular leak syndrome
7 induced by high doses of interleukin-2. *Intensive Care Med* 19: S19-28
- 8 64. Oehmcke S, Shannon O, von Köckritz-Blickwede M, Mörgelin M, Linder A,
9 Olin AI, Björck L, Herwald H (2009) Treatment of invasive streptococcal infection
10 with a peptide derived from human high-molecular weight kininogen. *Blood* 114:
11 444-451. DOI blood-2008-10-182527 [pii]
12 10.1182/blood-2008-10-182527
- 13 65. Bernard GR, Vincent JL, Laterre PF, LaRosa SP, Dhainaut JF, Lopez-
14 Rodriguez A, Steingrub JS, Garber GE, Helterbrand JD, Ely EW, Fisher CJ, Jr. (2001)
15 Efficacy and safety of recombinant human activated protein C for severe sepsis. *N*
16 *Engl J Med* 344: 699-709
17
18
19



1 Figure Legend:

2

3 Fig. 1: **The contact system.** Assembly of contact system factors on a negatively
4 charged surface activates FXII. FXII activates FXI that triggers the intrinsic
5 pathway of coagulation and plasma kallikrein. Plasma kallikrein cleaves HK,
6 followed by the release of the proinflammatory peptide BK.